Recently issued, new guidance from the FDA helps expand availability and access to naloxone for harm reduction programs. The guidance clarifies a public health emergency exclusion and exemption from requirements of the Drug Supply Chain Security Act (DSCSA) regarding the distribution of FDA-approved naloxone products to harm reduction programs and includes a related compliance policy. Although this guidance is immediately in effect, the FDA is accepting comments.
- Ann Tucker